Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
By Ben Glickman
Ultragenyx Pharmaceutical agreed to pay $6 million to resolve allegations by the Justice Department related to false Medicare and Medicaid claims.
The DOJ said Thursday the allegations related to Ultragenyx paying for free genetic tests for patients, as well as buying test results to induce prescriptions of its drug Crysvita, a treatment for X-linked hypophosphatemia, or XLH.
Insurers may require a genetic test indicating XLH before prescribing Crysvita, and the DOJ said Ultragenyx paid a genetic testing laboratory to conduct testing on patients for free and provide results to health-care providers.
DOJ argued Ultragenyx caused the submission of false claims to Medicare and Medicaid by paying for these tests as a form of kickback.
DOJ alleged Ultragenyx also paid the laboratory to provide test results to the company, which were then used for marketing Crysvita.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 17:30 ET (22:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth